Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

NCT01471106 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dasatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]